Recognition and results

XPRIZE recognition and measurable change in eight weeks

Healthy Longevity Clinic's program reached the Top 40 of XPRIZE Healthspan. In a small proof-of-concept study, statistically significant pre/post changes were detectable within eight weeks.

Recognized by XPRIZE Healthspan

Healthy Longevity Clinic was a 2025 XPRIZE Healthspan Milestone 1 award recipient. The program evaluated in the competition combined a measured starting point, coordinated care and repeat measurement. Each client’s plan is adapted to their health, priorities and clinical assessment.

Measurable change within eight weeks

Several measures showed statistically significant pre/post improvement during the eight-week program, including a DNA-methylation pace-of-aging measure, HbA1c and Timed Up and Go. The short study window is practically encouraging: progress was measurable in weeks, supporting earlier reassessment during care. This was a single-arm study with 10 participants and no randomized control group. It cannot prove that the program caused every change or predict how quickly an individual client will improve.

Design and participants

The source report describes a prospective, single-arm, open-label, within-participant pre/post feasibility evaluation. Ten participants completed an eight-week multimodal programme. Mean age at baseline was 78.1 years (range 71–84); seven participants were women and three were men. There was no randomized control group.

How the measurements were analysed

The report used paired pre/post analysis for each endpoint, 95% confidence intervals, paired effect sizes and exact sign-flip permutation tests. The number of paired observations varied from seven to ten for some measures. The primary table reports unadjusted p-values across many endpoints, so individual findings need cautious interpretation.

Completion and safety observations

All ten enrolled participants completed the programme and the report recorded no serious adverse events or post-enrolment withdrawals. It also recorded mild transient fatigue in several participants early in training. This small, selected cohort cannot establish safety for a wider population or for each component of the combined programme.

Study summary

Design, participants, findings and limits

Study design
Prospective, single-arm, open-label, within-participant pre/post feasibility evaluation. No randomized control group.
Participants
Ten participants completed the programme. Mean age 78.1 years (range 71–84); seven women, three men.
Duration
Eight weeks.
Main findings
Statistically significant pre/post improvement in several measures, including a DNA-methylation pace-of-aging measure, HbA1c and Timed Up and Go.
Limitations
Small, selected cohort with no control group; unadjusted p-values across many endpoints; findings cannot establish causation, safety for a wider population, or the effect of any single component.

Questions about the study or the method?

Our research team answers scientific questions about the evaluation, its design and its limitations.

Ask the research team